Venmax Drugs and Pharmaceuticals Limited (BOM:531015)
India
· Delayed Price · Currency is INR 23.85
+0.74 (3.20%)
At close: Mar 9, 2026
BOM:531015 Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2020 - 2016 |
| Revenue | 44.14 | 8.07 | - | - | - | 1.68 | Upgrade
|
| Revenue Growth (YoY) | 830.42% | - | - | - | - | -64.45% | Upgrade
|
| Cost of Revenue | 39.21 | 7.95 | 0.1 | - | - | 2.94 | Upgrade
|
| Gross Profit | 4.93 | 0.12 | -0.1 | - | - | -1.26 | Upgrade
|
| Selling, General & Admin | 1.75 | 0.47 | 0.23 | 0.3 | 0.19 | 0.63 | Upgrade
|
| Other Operating Expenses | 4.84 | 10.07 | 0.73 | 1.55 | 1.08 | -0.38 | Upgrade
|
| Operating Expenses | 6.64 | 10.6 | 1.02 | 1.94 | 1.36 | 0.35 | Upgrade
|
| Operating Income | -1.71 | -10.48 | -1.12 | -1.94 | -1.36 | -1.62 | Upgrade
|
| Other Non Operating Income (Expenses) | 10.91 | 10.52 | 1.99 | 4.19 | 19.83 | - | Upgrade
|
| EBT Excluding Unusual Items | 9.19 | 0.05 | 0.87 | 2.26 | 18.47 | -1.62 | Upgrade
|
| Asset Writedown | -0.19 | -0.19 | - | - | - | - | Upgrade
|
| Pretax Income | 9 | -0.14 | 0.87 | 2.26 | 18.47 | -1.62 | Upgrade
|
| Income Tax Expense | 0.28 | -0.04 | 0.22 | 0 | 0 | 0.01 | Upgrade
|
| Net Income | 8.72 | -0.11 | 0.65 | 2.26 | 18.46 | -1.62 | Upgrade
|
| Net Income to Common | 8.72 | -0.11 | 0.65 | 2.26 | 18.46 | -1.62 | Upgrade
|
| Net Income Growth | - | - | -71.41% | -87.78% | - | - | Upgrade
|
| Shares Outstanding (Basic) | 6 | 5 | 5 | 5 | 5 | 5 | Upgrade
|
| Shares Outstanding (Diluted) | 6 | 5 | 5 | 5 | 5 | 5 | Upgrade
|
| Shares Change (YoY) | 22.02% | - | - | - | 0.00% | - | Upgrade
|
| EPS (Basic) | 1.37 | -0.02 | 0.12 | 0.43 | 3.52 | -0.31 | Upgrade
|
| EPS (Diluted) | 1.37 | -0.02 | 0.12 | 0.43 | 3.52 | -0.31 | Upgrade
|
| EPS Growth | - | - | -72.09% | -87.78% | - | - | Upgrade
|
| Free Cash Flow | -115.49 | -22.9 | 0.02 | -0.03 | 19.05 | 2.64 | Upgrade
|
| Free Cash Flow Per Share | -18.18 | -4.37 | 0.00 | -0.01 | 3.64 | 0.50 | Upgrade
|
| Gross Margin | 11.16% | 1.52% | - | - | - | -75.35% | Upgrade
|
| Operating Margin | -3.88% | -129.77% | - | - | - | -96.38% | Upgrade
|
| Profit Margin | 19.76% | -1.30% | - | - | - | -96.78% | Upgrade
|
| Free Cash Flow Margin | -261.66% | -283.69% | - | - | - | 157.18% | Upgrade
|
| EBITDA | -1.67 | -10.41 | -1.05 | -1.86 | -1.27 | -1.51 | Upgrade
|
| EBITDA Margin | -3.78% | -128.97% | - | - | - | -90.22% | Upgrade
|
| D&A For EBITDA | 0.05 | 0.06 | 0.07 | 0.08 | 0.09 | 0.1 | Upgrade
|
| EBIT | -1.71 | -10.48 | -1.12 | -1.94 | -1.36 | -1.62 | Upgrade
|
| EBIT Margin | -3.88% | -129.77% | - | - | - | -96.38% | Upgrade
|
| Effective Tax Rate | 3.12% | - | 25.74% | 0.04% | 0.02% | - | Upgrade
|
| Revenue as Reported | 55.05 | 18.61 | 1.99 | 4.19 | 19.83 | 3.49 | Upgrade
|
| Advertising Expenses | - | 0.07 | - | - | - | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.